Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1Combination Product: Ravulizumab OBDS1件: Ravulizumab (Ravulizumab)1件: Ravulizumab (Ravulizumab, Ravulizumab) 💬 1件: C5 💬 11件: Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬1件: 62 💬
2RAVULIZUMAB1件: Ravulizumab (Ravulizumab)1件: Ravulizumab (Ravulizumab, Ravulizumab) 💬 1件: C5 💬 11件: Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬7件: 2, 11, 13, 50, 62, 66, 109 💬
3ULTOMIRIS ™ (ravulizumab-cwvz)1件: Ravulizumab (Ravulizumab)1件: Ravulizumab (Ravulizumab, Ravulizumab) 💬 1件: C5 💬 11件: Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬1件: 62 💬